Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00985556
First received: September 25, 2009
Last updated: October 19, 2011
Last verified: September 2009

September 25, 2009
October 19, 2011
January 2009
Not Provided
Progression-free survival [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00985556 on ClinicalTrials.gov Archive Site
Time to progression [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer
Randomized Phase II Study of S-1 (SOX) or Capecitabine (XELOX) in Combination With Oxaliplatin in Patients With Recurrent or Metastatic Gastric Cancer

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, S-1, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether giving oxaliplatin together with S-1 is more effective than giving oxaliplatin together with capecitabine.

PURPOSE: This randomized phase II trial is studying how well giving oxaliplatin together with S-1 works compared to oxaliplatin given together with capecitabine in treating patients with recurrent, metastatic, or unresectable gastric cancer.

OBJECTIVES:

Primary

  • To evaluate the time to progression in patients with recurrent or metastatic gastric cancer treated with oxaliplatin in combination with S-1 vs capecitabine.

Secondary

  • To assess progression-free survival, overall response, disease-control rate, time-to-treatment failure, response duration, time to response, overall survival, safety, quality of life, pharmacogenetics, and psychologic distress/coping strategy.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
  • Arm II: Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.

Courses in both arms repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 2 months for 6 months.

Interventional
Phase 2
Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Gastric Cancer
  • Drug: capecitabine
    Given orally
  • Drug: oxaliplatin
    Given IV
  • Drug: tegafur-gimeracil-oteracil potassium
    Given orally
  • Experimental: Arm I
    Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
    Interventions:
    • Drug: oxaliplatin
    • Drug: tegafur-gimeracil-oteracil potassium
  • Experimental: Arm II
    Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
    Interventions:
    • Drug: capecitabine
    • Drug: oxaliplatin
Kang JI, Chung HC, Jeung HC, Kim SJ, An SK, Namkoong K. FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. Psychoneuroendocrinology. 2012 Sep;37(9):1569-76. Epub 2012 Mar 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
130
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the stomach
  • Unresectable advanced disease or recurrent disease after resection
  • At least one radiographically documented (CT scan or MRI) measurable or evaluable lesion in a previously non-irradiated area according to RECIST
  • No clinical evidence of brain metastases or history of other CNS disease unless adequately treated

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Estimated life expectancy > 3 months
  • Hemoglobin ≥ 9 g/dL
  • White blood cell ≥ 4,000/µL
  • ANC ≥ 2,000/µL
  • Platelets ≥ 100,000/µL
  • Bilirubin ≤ 1.25 times upper limit of normal (ULN) (≤ 2.0 times ULN if hepatic metastasis present)
  • Serum creatinine ≤ 1.5 times ULN
  • Creatinine clearance ≥ 60 mL/min
  • AST/ALT ≤ 3.0 times ULN (≤ 5.0 times ULN if hepatic metastasis present)
  • Alkaline phosphatase ≤ 3.0 times ULN (≤ 5.0 times ULN if bone metastasis present)
  • Must have an intact gastrointestinal tract
  • Able to take oral medications
  • No medically uncontrolled severe infections or complications
  • No prior malignancy other than gastric cancer in the last 5 years except for basal cell cancer of the skin or preinvasive cancer of the cervix
  • Not pregnant or nursing
  • No neuropathy ≥ grade 2
  • No clinically relevant heart disease
  • No evidence of past medical history or psychosocial dysfunction that contraindicates the use of an investigational drug or puts the patient at risk
  • No dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
  • No uncontrolled hepatitis B or C, chronic liver disease, or diabetes mellitus
  • No other evidence of inappropriate suspicious condition

PRIOR CONCURRENT THERAPY:

  • No prior chemotherapy for advanced or recurrent disease

    • Prior adjuvant chemotherapy allowed if finished > 6 months before start of study treatment
  • No prior therapeutic radiotherapy

    • Prior palliative radiotherapy allowed if it was not done for primary, evaluable, or intraabdominal lesions
  • No prior capecitabine or oxaliplatin
  • No other concurrent chemotherapy or radiotherapy (except localized radiotherapy for pain relief)
  • No concurrent chemically related analogues, such as warfarin, phenytoin, or allopurinol
  • No concurrent steroid therapy except as follows:

    • Prophylactic use for hypersensitivity control or antiemetic purpose allowed
    • Chronic low dose of steroid (less than methylprednisolone 20 mg or equivalent dose) allowed
Both
18 Years and older
No
Korea, Republic of
 
NCT00985556
CDR0000650368, YONSEI-4-2007-0296
Not Provided
Not Provided
Yonsei University
Not Provided
Principal Investigator: Hyun C. Chung, MD, PhD Yonsei University
National Cancer Institute (NCI)
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP